[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354358-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354358-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","c-myc-induced-therapy-resistance-in-leukemia-mechanisms-and-emerging-therapeutic-opportunities","c-Myc-Induced Therapy Resistance in Leukemia: Mechanisms and Emerging Therapeutic Opportunities","","Dysregulation of the c-Myc oncogene is a pivotal event in leukemia pathogenesis and therapy resistance. This review synthesizes current evidence showing that c-Myc enhances proliferation, suppresses apoptosis, and upregulates immune checkpoints such as PD-L1, linking its overexpression to poor outcomes across leukemia subtypes. Direct c-Myc targeting is difficult, so indirect epigenetic modifiers, transcriptional disruption via CDK9 inhibitors, and combination therapies are highlighted to suppress oncogenic activity and overcome resistance, supporting improved clinical management.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/c-myc-induced-therapy-resistance-in-leukemia-mechanisms-and-emerging-therapeutic-opportunities/354358/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/c-myc-induced-therapy-resistance-in-leukemia-mechanisms-and-emerging-therapeutic-opportunities/354358.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is c-Myc dysregulation important in leukemia?","Question",{"text":63,"@type":64},"c-Myc dysregulation is central to leukemia pathogenesis and therapy resistance, driving leukemogenesis by increasing proliferation, inhibiting apoptosis, and elevating immune checkpoint activity such as PD-L1.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence links c-Myc overexpression to treatment outcomes?",{"text":68,"@type":64},"The review states that c-Myc overexpression is associated with poor treatment outcomes across multiple leukemia subtypes.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic approaches are suggested when direct c-Myc targeting is difficult?",{"text":72,"@type":64},"The review highlights indirect strategies including BET inhibitors (epigenetic modifiers), CDK9 inhibitors (transcriptional disruption), and combination therapies to suppress c-Myc oncogenic activity and overcome resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354358,1790189902,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nc-Myc-Induced Therapy Resistance in Leukemia: Mechanismsand Emerging Therapeutic Opportunities  \nAli Rafat 1,†, Javad Arabpour 2,†, Haniye Yarahmadi 3, Hediye Khalkhali 3, Zeinab Mazloumi 4,  \nSeyyede Sepide Ashraf Moosavi 5, Hossein Kalarestaghi 6, Khadijeh Dizaji Asl 7, * and Reza Nejati 8, *  \nAcademic Editors: Walid Shalata, Abed Agbarya and MarkoJakopovic Received: 14 May 2026  \nRevised: 7 June 2026  \nAccepted: 11 June 2026  \nPublished: 16 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran. 87159-87411; [alirafat1370@gmail.com](alirafat1370@gmail.com)  \n2 Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. 14115-154; [bio.javad.arabpour@gmail.com](bio.javad.arabpour@gmail.com)  \n3 Department of Microbiology, Faculty of Basic Sciences, Tabriz Branch, Islamic Azad University, Tabriz, Iran. 51579-44511; [haniye.yarahmadi@iau.ir](haniye.yarahmadi@iau.ir) (H.Y.); [hediye.khalkhali3029@iau.ir](hediye.khalkhali3029@iau.ir) (H.K.)  \n4 Department of Medical Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. 51579-44511; [zb.mazloumi@gmail.com](zb.mazloumi@gmail.com)  \n5 Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran. 87159-87411; [sepideh.amoosavi@gmail.com](sepideh.amoosavi@gmail.com)  \n6 Research Laboratory for Embryology and Stem Cell, Department of Anatomical Sciences, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran. 56189-58911  \n7 Department of Histopathology and Anatomy, TaMS.C, Islamic Azad University, Tabriz, Iran. 51579-44511  \n8 Department of Pathology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, USA. PA 19111  \n* Correspondence: [kh.dizaji@iau.ac.ir](kh.dizaji@iau.ac.ir) (K.D.A.); [reza.nejati@fccc.edu](reza.nejati@fccc.edu) (R.N.)† These authors contributed equally to this work.  \nAbstract  \nDysregulation of the c-Myc oncogene is a pivotal event in leukemia pathogenesis and therapy resistance. This review synthesizes current evidence, illustrating that c-Myc drives leukemogenesis by enhancing proliferation, inhibiting apoptosis, and upregulating immune checkpoints like PD-L1 . Its overexpression is linked to poor treatment outcomes across various leukemia subtypes. Directly targeting c-Myc remains challenging; however, indirect epigenetic modifiers (BET inhibitors), transcriptional disruption (CDK9 inhibitors), and combination therapies emerge as promising strategies to suppress its oncogenic activity and overcome resistance, paving the way for improved clinical management.  \nKeywords: c-Myc; leukemia; oncogene; leukemogenesis; therapy resistance; targeted therapy  \n1. Introduction  \nLeukemia represents a heterogeneous group of hematologic malignancies characterized by uncontrolled proliferation and differentiation arrest of hematopoietic precursors in the bone marrow [1] . It is broadly categorized into four main types: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML) [2] . According to the 2022 Global Reports, leukemia is the second most common hematological malignancy worldwide after non-Hodgkin lymphoma. In adults, AML is the most frequently diagnosed subtype, whereas in children, ALL is the most prevalent [3] .  \nThe pathogenesis of leukemia is fundamentally driven by the dysregulation of protooncogenes, normal cellular genes that regulate cell growth, division, and differentiation. When these genes become constitutively activated through chromosomal translocations,  \npoint mutations, or aberrant transcriptional activation, they drive uncont","cbCaimAkmrghmumC","https://ap.wps.com/l/cbCaimAkmrghmumC","pdf",2349102,31,"English","# Abstract\n# Introduction\n## Leukemia overview and classification\n## Protooncogene dysregulation and oncogenic drivers\n## The Myc family and c-Myc genomic/protein features\n# Mechanisms of c-Myc–driven malignant transformation\n## Proliferation, differentiation, and metabolic reprogramming\n## Apoptosis resistance and immune evasion\n## Therapeutic implications and emerging strategies","[{\"question\":\"Why is c-Myc dysregulation important in leukemia?\",\"answer\":\"c-Myc dysregulation is central to leukemia pathogenesis and therapy resistance, driving leukemogenesis by increasing proliferation, inhibiting apoptosis, and elevating immune checkpoint activity such as PD-L1.\"},{\"question\":\"What evidence links c-Myc overexpression to treatment outcomes?\",\"answer\":\"The review states that c-Myc overexpression is associated with poor treatment outcomes across multiple leukemia subtypes.\"},{\"question\":\"What therapeutic approaches are suggested when direct c-Myc targeting is difficult?\",\"answer\":\"The review highlights indirect strategies including BET inhibitors (epigenetic modifiers), CDK9 inhibitors (transcriptional disruption), and combination therapies to suppress c-Myc oncogenic activity and overcome resistance.\"}]","c-Myc-Induced Therapy Resistance in Leukemia: Mechanisms and Emerging Therapeutic Opportunities | PDF",1790110296,78,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e233c9b452d5d0a7c6e239463b44d57.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f21cce59794a80ff99e7d1ed97c85dfd.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f1e267246ff2a83340fccddfe2b223a.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1597c4e6a3f4271d34636515d19f56ba.webp",980,1385]